Clinical information
Puberty describes the phase of human development that leads to sexual and physical maturity. It begins with endocrine changes in the central nervous system.
At the onset of puberty, there is a pulsatile release of gonadotropin-releasing hormone (GnRH) in the hypothalamus. The production of GnRH subsequently leads to an increased secretion of luteinising hormone (LH) and gonadotropin (follicle-stimulating hormone, FSH), which in turn stimulate the production of oestrogens and androgens in the gonads.
In girls, puberty usually begins a few years earlier than in boys. With the shift of hormones come multiple physical changes, which typically include a growth spurt and the development of underarm and pubic hair in both sexes. In young males the voice deepens and facial hair begins to grow. Young females experience an increase in fat mass, breast development and the menarche (the first period).
If these sexual characteristics develop before the age of approximately 9–12 years, this is referred to as precocious puberty. In contrast, if puberty starts after this age range, it is considered delayed.
Diagnostics
Puberty describes the phase of human development that leads to sexual and physical maturity. It begins with endocrine changes in the central nervous system.
At the onset of puberty, there is a pulsatile release of gonadotropin-releasing hormone (GnRH) in the hypothalamus. The production of GnRH subsequently leads to an increased secretion of luteinising hormone (LH) and gonadotropin (follicle-stimulating hormone, FSH), which in turn stimulate the production of oestrogens and androgens in the gonads.
In girls, puberty usually begins a few years earlier than in boys. With the shift of hormones come multiple physical changes, which typically include a growth spurt and the development of underarm and pubic hair in both sexes. In young males the voice deepens and facial hair begins to grow. Young females experience an increase in fat mass, breast development and the menarche (the first period).
If these sexual characteristics develop before the age of approximately 9–12 years, this is referred to as precocious puberty. In contrast, if puberty starts after this age range, it is considered delayed.
| Technology | Parameter | Substrate | Species | Calibration | Ig Class | Format | Order No. |
|---|---|---|---|---|---|---|---|
| ELISA |
17-OH-Progesterone ELISA |
antibody-coated microplate wells | 0/0.15/0.5/1.5/3/7.5/20 ng/ml |
96 x 01 |
EQ 6163-9601 | ||
| ChLIA | IDS 17-OH Progesterone | Streptavidin-coated magnetic particles |
quantitative |
100 x 01 |
IS-51001 | ||
| ChLIA | IDS 17-OH Progesterone Control Set | 2 x 1.0 ml Control 1/2/3 | 17-OH Progesterone |
3 concentration levels |
IS-51301 | ||
| ChLIA | IDS Total Testosterone | Streptavidin-coated magnetic particles |
quantitative |
100 x 01 |
IS-50001 | ||
| ChLIA | IDS Total Testosterone Control Set | 2 x 1.0 ml Control 1/2/3 | Testosterone |
3 concentration levels |
IS-50301 | ||
| ELISA |
Androstenedione ELISA |
antibody-coated microplate wells | 0/0.1/0.3/1/3/10 ng/ml |
96 x 01 |
EQ 6153-9601 | ||
| ChLIA | IDS Androstenedione | Antibody-coated magnetic particles |
quantitative |
100 x 01 |
IS-54001 | ||
| ChLIA | IDS Androstenedione Calibrator Set | 1 x 1.0 ml Calibrator 1/2/3/4/5/6 | Androstenedione |
6 concentration levels |
IS-54201 | ||
| ChLIA | IDS Androstenedione Control Set | 2 x 1.0 ml Control 1/2 | Androstenedione |
2 concentration levels |
IS-54301 | ||
| ELISA |
Dehydroepiandrosterone (DHEA) ELISA |
antibody-coated mircoplate wells | quantitative |
96 x 01 |
EQ 6154-9601-1 | ||
| ChLIA | IDS SHBG | Streptavidin-coated magnetic particles |
quantitative |
100 x 01 |
IS-56001 | ||
| ChLIA | IDS SHBG Control Set | 2 x 1.0 ml Control 1/2/3 | Sexual hormone-binding globulin (SHBG) |
3 concentration levels |
IS-56301 | ||
| ELISA |
Estrone ELISA |
antibody-coated microplate wells | 0/20/60/200/600/2000 pg/ml |
96 x01 |
EQ 6165-9601-1 | ||
| ELISA |
Dihydrotestosterone (DHT) ELISA |
antibody-coated microplate wells | 0/25/100/250/500/1000/2500 pg/ml |
96 x 01 |
EQ 6152-9601-1 | ||
|
* For research use only, not for in vitro diagnostic use in the sense of EU directive 98/79/EC. 1 Product manufactured by third party. Please contact your local Euroimmun representative for more information. | |||||||